Physician profile
Mary Hebert Dawson
NPI 1447454251
$2,727.37
in general payments reported to CMS, 2019-2025
23 companies · $886 in 2025
The $886 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $157 · 2021: $39.88 · 2022: $123 · 2023: $270 · 2024: $841 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,988.76 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $649.15 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $596.06 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $342.60 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $236.42 | 2019-2025 | |
| Lilly USA, LLC | $177.61 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.77 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $84.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $59.24 | 2019-2025 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $51.15 | 2019 | |
| Glaxosmithkline, LLC. | $46.64 | 2020-2025 | Arexvy, Shingrix |
| Dexcom, INC. | $45.53 | 2023-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.98 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $43.22 | 2019-2022 | |
| Esperion Therapeutics, INC. | $36.87 | 2022-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $36.23 | 2024-2025 | Eliquis, Camzyos |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $35.75 | 2024-2025 | Gvoke Hypopen |
| Amarin Pharma, INC. | $32.05 | 2019-2020 | |
| Medtronic, INC. | $29.98 | 2024-2025 | Intellis Adaptivestim |
| Assertio Therapeutics, INC. | $21.60 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.32 | 2022 | |
| Daiichi Sankyo INC. | $21.19 | 2022 | |
| Currax Pharmaceuticals LLC | $16.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.